Sports Medicine Review (Springer 2026): Evidence for 12 Peptides in Athletic Use

In spring 2026 the Springer Nature journal Sports Medicine published a comprehensive review titled "Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance" (DOI: 10.1007/s40279-026-02437-0). The paper consolidates the current evidence base for twelve peptides that are being discussed in sports medicine and classifies them by mechanism, clinical evidence, safety profile, and regulatory status.

The review is relevant to the research community for several reasons. It appears in one of the most respected journals in the field, it covers a class of compounds that has increasingly slipped into the grey zone between approved medicines and unregulated research chemicals, and it names the data gaps that currently make serious assessment difficult.

Note: research purposes only

This article summarises the findings published in Sports Medicine on peptides in the sports medicine context. It is not medical or therapeutic advice, not doping guidance, and not a statement about human performance enhancement. The substances discussed are classified as research chemicals in the EU and are not intended for consumption by humans or animals.

What is Sports Medicine (Springer)?

Sports Medicine is a peer-reviewed journal published by Springer Nature. Since the 1980s it has addressed the physiological, clinical, and pharmacological side of sport and regularly ranks among the most-cited titles in the sports science field. Reviews in this journal carry weight because they are typically methodologically rigorous and evaluate a well-delimited body of evidence.

The 2026 review was first released as a preprint on Preprints.org (202512.1011) and then converted into the final journal version. It addresses a dual audience: sports physicians confronted in their practice with questions about peptides, and regulators who need an overview of the current state given the 2026 FDA reorganisation (see FDA Cat-2 repeal April 2026 and US peptide regulation 2026).

Scope of the review

The paper covers twelve peptides, grouped roughly by mechanism of action:

Regenerative / tissue-restorative: BPC-157, TB-500, Thymosin Beta-4 (Tβ4), GHK-Cu
Mitochondrial / metabolic: MOTS-C, SS-31 (Elamipretide)
Growth hormone axis: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, AOD-9604
Muscle / myostatin: FS-344 (Follistatin-344)

The review consistently distinguishes approved peptides (Tesamorelin, the only FDA-approved peptide in the list, for the narrow indication of HIV-associated lipodystrophy) from unapproved compounds that surface in sports medicine practice.

Regenerative peptides: BPC-157, TB-500/Tβ4, GHK-Cu

BPC-157

BPC-157 is a synthetic pentadecapeptide derived from a protective protein in human gastric juice. The Springer review names its main mechanisms clearly: VEGF upregulation and angiogenesis, modulation of the NO system, activation of the FAK-Paxillin pathway, and effects on growth factors such as EGF, FGF, and IGF-1.

The evidence base is described as preclinically strong, clinically thin. There are many animal models covering tendons, ligaments, the GI tract and wound healing, but only isolated human data. The review cites a recent systematic overview that could identify only a single clinical study, and a 2025 human IV pilot on safety (see BPC-157 IV pilot 2025).

Alongside, the authors point to the parallel narrative review "Regeneration or Risk? BPC-157 in Musculoskeletal Healing" (PMC12446177) and "Emerging Use of BPC-157 in Orthopaedic Sports Medicine" (PMC12313605). For more on current findings see BPC-157 new studies on tendons, muscle, heart rhythm and the product overview BPC-157 buy.

TB-500 and Thymosin Beta-4

The review carefully distinguishes TB-500 from Thymosin Beta-4. Tβ4 is a naturally occurring 43-amino-acid peptide, while TB-500 is usually a shorter active fragment, often referred to as Ac-LKKTETQ. This is not a semantic quibble: part of the cited literature comes from Tβ4 research (heart, skin, cornea) and does not automatically transfer to TB-500.

The core mechanistic themes are actin binding, cell migration, progenitor cell activation, and inflammation modulation. The safety profile is classified as preclinically unremarkable, but inadequately documented in humans. More context: TB-500 buy, Wolverine Stack: BPC-157 + TB-500.

GHK-Cu

The copper tripeptide GHK-Cu is highlighted mainly for its broad gene regulation and the documented effects on collagen synthesis, wound healing, and extracellular matrix remodelling. The skin and connective tissue data are of interest for sports medicine use, while systemic regenerative claims are discussed cautiously. Product and research context: GHK-Cu buy and GHK-Cu copper peptide for longevity.

Broader framework: Healing peptides overview.

Mitochondrial and metabolic peptides: MOTS-C, SS-31

MOTS-C

MOTS-C is a mitochondrially encoded 16-amino-acid peptide that has emerged in recent years as an endogenous regulator of energy metabolism. The review identifies it as an interesting candidate for exercise tolerance and metabolic flexibility, but notes that human evidence is still at a very early stage. Mechanistically it points to AMPK activation and the recent CK2α work; see MOTS-C CK2α mechanism 2024 and MOTS-C buy.

SS-31 (Elamipretide)

SS-31, known clinically as Elamipretide, is a mitochondrially targeted tetrapeptide that binds cardiolipin and stabilises the inner mitochondrial membrane. The Springer review notes that SS-31 is among the peptides with a relatively robust clinical database, in particular from phase II/III work on primary mitochondrial disease and heart failure, even if individual trials have missed endpoints.

For the sports medicine discussion SS-31 therefore remains a serious mechanistic candidate, but not yet a performance compound validated by randomised exercise trials. Further reading: SS-31 buy and mitochondrial peptides compared.

Growth hormone axis: CJC-1295, Ipamorelin, Sermorelin, Tesamorelin, AOD-9604

This is the most detailed section of the review, because GH-axis peptides are the most frequent questions in sports medicine practice.

Sermorelin is a 29-amino-acid analogue of endogenous GHRH (Growth Hormone Releasing Hormone). It has historically been used for diagnostics and paediatric growth research and therefore has a correspondingly supported safety record. More: Sermorelin buy.

CJC-1295 is a modified GHRH analogue with an extended half-life (in its DAC form) that still preserves pulsatile physiological GH release. Ipamorelin is a selective ghrelin receptor agonist (GHS-R1a) often combined with CJC-1295 because the two substances address different axes. Product and literature context: CJC-1295 + Ipamorelin buy, Ipamorelin buy.

Tesamorelin is the only peptide in the review with an FDA approval, and a narrow one at that: HIV-associated lipodystrophy. Its efficacy on visceral fat is clinically established and its safety and long-term profile data are comparatively solid. Product: Tesamorelin buy.

AOD-9604 is a synthetic fragment (aa 176–191) of human growth hormone, originally developed for obesity studies. The review evaluates AOD-9604 soberly: the preclinical data on fat mobilisation are consistent, but human trials show significantly more muted effects than originally hoped. More: AOD-9604 buy.

Muscle and myostatin axis: FS-344

FS-344 is an isoform of follistatin and acts as a myostatin inhibitor. Of the twelve compounds discussed it is the least established. The review notes that follistatin-based approaches show intriguing effects on muscle mass and function in preclinical myopathy models, but that human data are largely absent and the pharmacokinetic profile has not been sufficiently characterised.

For FS-344 in particular, the authors explicitly warn about the grey market: what circulates under this name in unregulated trade is rarely well documented with respect to purity, sequence fidelity, and actual bioactivity.

The grey market problem: regulation, quality, research vs. therapy

A central strand of the review is not about the molecules themselves but about their regulatory context. The authors describe a parallel market of unapproved peptides operating outside classical drug surveillance.

The FDA had historically placed many of these compounds in "Bulk Category 2", flagging them as too problematic for compounding under pharmacist prescription. In 2026 this category was repealed and replaced by an explicit list of prohibited substances; see FDA Cat-2 repeal April 2026 and US peptide regulation 2026: FDA changes. For Europe this is not directly binding, but symbolically relevant: it shifts the criteria for what counts as "clinically acceptable" and what as a pure research substance.

The quality question runs through the entire review. Purity, sequence fidelity, endotoxin load, and correct identity of a peptide can only be established through independent analytical evidence. In regulated research HPLC, MS and CoA documentation are standard; on the grey market they are the exception.

Relevance for EU research labs

For EU researchers the value of the Springer review lies primarily in its academic reference framework. It orders mechanisms, classifies evidence, names gaps, and thereby creates a basis for placing individual peptides seriously within one's own research design. It does not replace a project-specific literature search, but is a clean starting point.

What the review calls for

The authors conclude with two core demands. First, more methodologically sound human studies. The jump from preclinical models to robust clinical endpoints is the critical bottleneck for almost every peptide discussed. Second, clearer regulatory frameworks. The situation in which Tesamorelin as an approved drug and BPC-157 as a research chemical are discussed through the same forums, podcasts and online shops is not tenable in the authors' view, either for patients or for serious research.

The review stresses that these demands do not conflict with ongoing peptide research. On the contrary, only with reliable human data and clean regulation can mechanistically plausible candidates be moved out of the grey zone and into mainstream science.

Companion review: Regeneration or Risk?

As a companion to the Springer paper, the narrative review "Regeneration or Risk? BPC-157 in Musculoskeletal Healing" (PMC12446177) is worth reading. It focuses on BPC-157, classifies the evidence by tissue type (tendon, muscle, ligament, bone) and is methodologically less strict than the Springer review, but more hands-on in its presentation of individual animal studies. Together the two works produce a relatively complete picture of the current state of discussion.

Summary

The 2026 Springer review is the most comprehensive formal stocktaking to date of twelve peptides relevant to sports medicine. It classifies mechanisms cleanly, separates approved from unapproved compounds, and names the data gaps openly. For EU research labs it offers a serious reference framework, but does not replace subject-specific literature work.

The key messages in brief: mechanistic plausibility for many peptides is good, human evidence is almost uniformly thin, the regulatory situation is in motion, and the quality question around traded substances is a separate topic that should not be conflated with the question of pharmacology.

The reviewed peptides at PeptidesDirect

We carry the peptides analysed in the Springer review in research quality:

Regenerative:

BPC-157 – tissue repair
TB-500 – muscle and tendon recovery
BPC-157 + TB-500 Mix – combination blend
GHK-Cu – copper peptide, wound healing

Mitochondrial:

MOTS-C – mitochondrial signalling peptide
SS-31 – cardiolipin-binding mitopeptide

Growth hormone axis:

CJC-1295 + Ipamorelin Mix – GHRH analogue plus GHS combination
Ipamorelin – selective GH secretagogue
Sermorelin – GHRH analogue
Tesamorelin – FDA-approved GHRH analogue
AOD-9604 – fragment 177–191 of human growth hormone

All products are supplied strictly for research purposes; purity data and batch CoAs available on request.